Efficacy of Continuing Anti-Angiogenic Agents in the Second-Line Treatment for Metastatic Colon Cancer Depending on the KRAS Mutation Status: A Meta-Analysis

Colorectal Oncology
doi 10.17650/2220-3478-2018-8-2-38-45
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Publishing House ABV Press

Related search

Modeling Efficacy of Bevacizumab Treatment for Metastatic Colon Cancer

Journal of Cancer
Oncology
2013English

Anti-Angiogenic Drugs for Second-Line Treatment of NSCLC Patients: Just New Pawns on the Chessboard?

Expert Opinion on Biological Therapy
Drug DiscoveryClinical BiochemistryPharmacology
2015English

Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting

Journal of Oncology
Oncology
2020English

Molecular Targeted Agents as Second-Line Treatment for Hepatocellular Carcinoma: A Meta-Analysis and Review

Oncotarget
Oncology
2017English

The Role of Anti-Egfr Agents in the First-Line Treatment of Advanced Esophago-Gastric Adenocarcinoma: A Meta-Analysis

Oncotarget
Oncology
2017English

Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature

PLoS ONE
Multidisciplinary
2015English

Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma

World Journal of Oncology
Cancer ResearchOncology
2013English

The Addition of Bevacizumab in the First-Line Treatment for Metastatic Colorectal Cancer: An Updated Meta-Analysis of Randomized Trials

Oncotarget
Oncology
2017English

Magnetic Resonance-Based Texture Analysis Differentiating KRAS Mutation Status in Rectal Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy